Directorate Change

Genus PLC

23 August 2023

 

For Immediate Release

23 August 2023

Genus plc

Non-Executive Director Retirement

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Lykele van der Broek, Non-Executive Director, has informed the Company of his intention to step down from the Genus Board, effective from the conclusion of the 2023 Annual General Meeting on 22 November 2023, after nine years' service as a Non-Executive Director.

Russell Reynolds has been retained and is in the process of identifying potential successors for Lykele.

Commenting on the retirement, Iain Ferguson, Chairman of Genus, said:

"On behalf of the Board I want to acknowledge Lykele's significant contributions to the Board's deliberations, bringing to the fore his experience and knowledge as a leader in growing agricultural businesses across global markets. We thank him for his contributions, we will miss his keen insight and business acumen during our Board discussions and wish him well for the future."

For further information please contact:

Genus:

Iain Ferguson, Chairman                                                               Tel: [phone]

Jorgen Kokke, Chief Executive

 Buchanan:

Charles Ryland /Chris Lane/ Verity Parker                           Tel: [phone]

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus' worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

END